← Patent-cliff monitor small molecule CREXONT CARBIDOPA; LEVODOPA
Loss of exclusivity December 2041 latest FDA-listed patent expiry
Drug detail Brand name CREXONT Active ingredient CARBIDOPA; LEVODOPA Strength 35MG;140MG Dosage form CAPSULE, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval August 2024 Marketing status RX
Listed patents Patent Expires Type 12303482 December 2041 use U-219 12295931 December 2041 use U-219 12303481 December 2041 use U-4005 11986449 December 2041 use U-219 12201596 December 2041 use U-4005 12109185 December 2041 use U-4005 12458616 December 2041 use U-219 12453710 December 2041 use U-1649 12263148 December 2041 use U-4005 12263149 December 2041 use U-4005 12447139 December 2041 use U-4005 12194150 December 2041 use U-219 12370163 December 2041 use U-4005 12303605 October 2034 product 12403099 October 2034 product 12491164 October 2034 product 11622941 October 2034 product 12178918 October 2034 product 12064521 October 2034 product 11357733 October 2034 product 11666538 October 2034 product 10987313 October 2034 product 10973769 October 2034 product 10688058 October 2034 product 10292935 October 2034 product 10098845 October 2034 product 12128141 October 2034 product 12178919 October 2034 product 12274793 October 2034 product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.